Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-45

Just prior to todays webinar, can anyone explain to me what happen with all this work we have undertaken when our licence to 1102 expires in September 2023, does Ionis just say thanks for the investigations you have done but we are not renewing your licence? below taken from last 4C
Intellectual Property Report (continued)
** ATL1102 and ATL1103 are protected internationally by other Ionis proprietary antisense technology patents
and applications to which Antisense Therapeutics has world-wide license including US7015315 with an expiry of
September 2023. For ATL1103 cases with expiry of 2024 and 2025 there will be no payments of annuity, renewal
and maintenance fees allowing these cases to lapse in due course before expiry without further payment of fees.